Table 1.
Baseline clinical characteristics
| All patients (n = 150) | T (n = 75) | CFS (n = 75) | P | |
|---|---|---|---|---|
| Age (year) | 58 (42–69) | 55 (42–68) | 60 (43–69) | 0.30 |
| Female | 77 (51%) | 43 (57%) | 34 (45%) | 0.19 |
| Hypertension | 79 (52%) | 41 (55%) | 38 (51%) | 0.74 |
| Diabetes | 20 (13%) | 10 (13%) | 10 (13%) | 1.00 |
| Ischaemic heart disease | 23 (15%) | 15 (20%) | 8 (11%) | 0.17 |
| eGFR (mL/m2) | 74 (60–90) | 71 (57–90) | 80 (64–90) | 0.31 |
| Daily PVC burden (%) | 22 (15–30) | 22 (15–30) | 21 (15–30) | 0.90 |
| LVEF (%) | 55 (44–60) | 55 (43–60) | 52 (44–60) | 0.94 |
| PVC QRS width (ms) | 160 (120–180) | 160 (148–180) | 160 (140–169) | 0.36 |
| Antiarrhythmic usea | 107 (71%) | 53 (71%) | 54 (72%) | 0.74 |
| LVOT originb | 71 (47%) | 35 (47%) | 36 (47%) | 1.00 |
Continuous variables are expressed as median and interquartile range.
CFS, irrigated contact force sensing manual ablation catheters; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; PVC, premature ventricular complex; T, traditional irrigated manual ablation catheters without contact force sensing capability.
a
Including β-blockers.
b
Including all left-sided sites of origin.